Roche Pharmaceutical Development and Sales Overview
Ipatasertib (RG7440, GDC-0068)
Highly selective small molecule inhibitor of Akt
Indication
Phase/study
# of patients
Design
Primary endpoint
■
Status
CT Identifier
"
"
"
ARM A: Ipatasertib plus abiraterone
ARM B: Placebo plus abiraterone
1L castration-resistant prostate cancer (CRPC)
rPFS in patients with PTEN loss tumors and overall population
Phase III
IPATential150
N=1,100
FPI Q2 2017
Recruitment completed Q1 2019
Study met co-primary endpoint in rPFS in patients with PTEN loss tumors Q2 2020
Data presented at ESMO 2020 and interim OS at ASCO 2022
Published in Lancet 2021; 398:131-142
NCT03072238
Akt-Protein Kinase B; PTEN=Phosphatase and Tensin homolog; rPFS=Radiographic progression-free survival; ESMO-European Society for Medical Oncology, ASCO-American Society of Clinical Oncology
Roche
104
OncologyView entire presentation